Listen

Press releases

Receive e-mail alerts

Internal link ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
December 08, 2023 at 12:30 PM UTC
Internal link ProQR Announces Third Quarter 2023 Operating and Financial Results
November 07, 2023 at 12:00 PM UTC
Internal link ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
November 06, 2023 at 12:00 PM UTC
Internal link ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
September 28, 2023 at 12:00 PM UTC
Internal link ProQR Therapeutics Provides Update on Ophthalmic Assets
September 27, 2023 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
September 07, 2023 at 12:00 PM UTC
Internal link ProQR Announces Second Quarter 2023 Operating and Financial Results
August 03, 2023 at 11:00 AM UTC
Internal link ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
August 01, 2023 at 11:00 AM UTC
Internal link ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit
July 06, 2023 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2023 Operating and Financial Results
May 16, 2023 at 11:00 AM UTC
Internal link ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023
May 09, 2023 at 12:00 PM UTC
Internal link ProQR Announces Upcoming Investor Conferences in April and May
April 20, 2023 at 12:00 PM UTC
Internal link ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
April 18, 2023 at 12:00 PM UTC
Internal link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
March 29, 2023 at 12:00 PM UTC
Internal link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
March 14, 2023 at 12:00 PM UTC
Internal link ProQR to Present at Upcoming Scientific and Industry Conferences
March 07, 2023 at 01:00 PM UTC
Internal link ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023
February 28, 2023 at 01:00 PM UTC
Internal link ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital
December 30, 2021 at 12:00 PM UTC
Internal link ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa
December 16, 2021 at 12:00 PM UTC
Internal link ProQR Announces Highlights from Analyst Event
November 18, 2021 at 09:01 PM UTC
Internal link ProQR to Webcast Virtual Analyst Event on November 18
November 11, 2021 at 12:00 PM UTC
Internal link ProQR Announces Upcoming Investor Conferences in November and December
November 08, 2021 at 09:30 PM UTC
Internal link ProQR Announces Third Quarter 2021 Operating and Financial Results
November 04, 2021 at 11:00 AM UTC
Internal link ProQR Appoints Theresa Heggie as Chief Commercial Officer
October 04, 2021 at 12:00 PM UTC
Internal link ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform
September 08, 2021 at 08:15 PM UTC

Press releases

Internal link ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

Internal link ProQR Announces Third Quarter 2023 Operating and Financial Results

Internal link ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

Internal link ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

Internal link ProQR Therapeutics Provides Update on Ophthalmic Assets

Internal link ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

Internal link ProQR Announces Second Quarter 2023 Operating and Financial Results

Internal link ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets

Internal link ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

Internal link ProQR Announces First Quarter 2023 Operating and Financial Results

Internal link ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

Internal link ProQR Announces Upcoming Investor Conferences in April and May

Internal link ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

Internal link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

Internal link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

Internal link ProQR to Present at Upcoming Scientific and Industry Conferences

Internal link ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023

Internal link ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital

Internal link ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa

Internal link ProQR Announces Highlights from Analyst Event

Internal link ProQR to Webcast Virtual Analyst Event on November 18

Internal link ProQR Announces Upcoming Investor Conferences in November and December

Internal link ProQR Announces Third Quarter 2021 Operating and Financial Results

Internal link ProQR Appoints Theresa Heggie as Chief Commercial Officer

Internal link ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform